John M. Burke, MD from Rocky Mountain Cancer Centers discusses Atezolizumab + Bendamustine & Obinutuzumab and no major safety signals in follicular lymphoma at the 2017 American Society of Hematology.
Atezolizumab + Bendamustine & Obinutuzumab – No major safety signals in follicular lymphoma
